Last reviewed · How we verify
Start antiplatelet monotherapy
Antiplatelet monotherapy reduces blood clot formation by inhibiting platelet aggregation through a single antiplatelet agent.
Antiplatelet monotherapy reduces blood clot formation by inhibiting platelet aggregation through a single antiplatelet agent. Used for Secondary prevention of cardiovascular events, Acute coronary syndrome, Stroke prevention.
At a glance
| Generic name | Start antiplatelet monotherapy |
|---|---|
| Sponsor | The George Institute for Global Health, China |
| Drug class | Antiplatelet agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Antiplatelet monotherapy works by blocking one of the key pathways involved in platelet activation and aggregation, thereby reducing the risk of thrombotic events. This is typically achieved through inhibition of platelet function via mechanisms such as cyclooxygenase inhibition, P2Y12 receptor antagonism, or phosphodiesterase inhibition. The approach is used to prevent cardiovascular events in patients at risk of atherothrombotic disease.
Approved indications
- Secondary prevention of cardiovascular events
- Acute coronary syndrome
- Stroke prevention
Common side effects
- Bleeding
- Gastrointestinal bleeding
- Dyspepsia
Key clinical trials
- Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial (NA)
- Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral HaemorrhaGe (ASPIRING)-Pilot Phase (PHASE3)
- ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study (PHASE4)
- PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction (PHASE4)
- Cilostazol Stroke Prevention Study for Antiplatelet Combination (PHASE4)
- Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - Venezuela
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: